Zacks Research Issues Negative Forecast for JAZZ Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Equities researchers at Zacks Research dropped their Q4 2026 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Thursday, September 24th. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings of $5.28 per share for the quarter, down from their prior forecast of $5.29. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $21.61 per share.

A number of other research firms also recently commented on JAZZ. Wells Fargo & Company upped their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 price objective on Jazz Pharmaceuticals in a report on Wednesday, August 26th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $289.37.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $232.35 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The firm has a market capitalization of $15.08 billion, a price-to-earnings ratio of 16.02, a price-to-earnings-growth ratio of 0.21 and a beta of 0.36. Jazz Pharmaceuticals has a one year low of $128.49 and a one year high of $266.38. The company has a 50 day moving average price of $248.25 and a 200 day moving average price of $228.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the business posted ($8.25) earnings per share. The firm’s quarterly revenue was up 15.5% on a year-over-year basis.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after purchasing an additional 111,735 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after buying an additional 517,514 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after buying an additional 1,129,995 shares during the last quarter. Bank of America Corp DE increased its position in shares of Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its stake in shares of Jazz Pharmaceuticals by 63.0% in the 4th quarter. Sofinnova Investments Inc. now owns 959,860 shares of the specialty pharmaceutical company’s stock valued at $163,176,000 after purchasing an additional 371,032 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In related news, CEO Renée Galá sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total transaction of $486,060.00. Following the completion of the sale, the chief executive officer directly owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the sale, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This trade represents a 53.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 92,121 shares of company stock valued at $23,001,022. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.